An Observational Study for Analysis of Mortality in Participants Who Participated in Previous 3 Studies of Galantamine
NCT ID: NCT00297414
Last Updated: 2012-04-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1083 participants
OBSERVATIONAL
2004-06-30
2005-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment
NCT00236574
A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment
NCT00236431
A Follow-up Study to Assess Safety and Tolerability of Galantamine Treatment in Individuals With Mild Cognitive Impairment
NCT00240695
A Study of the Safety and Effectiveness of Galantamine Hydrobromide in Patients With Alzheimer's Disease
NCT00297362
A Study of the Safety and Effectiveness of Galantamine Versus Placebo in the Treatment of Patients With Vascular Dementia or Mixed Dementia
NCT00261573
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with mild cognitive impairment
Patients with mild cognitive impairment who were treated with galantamine or placebo in previous 3 clinical studies.
No intervention
No study drug was administered to the patients. Data on vital status was obtained for patients with mild cognitive impairment who were treated with galantamine or placebo in previous 3 clinical studies.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No intervention
No study drug was administered to the patients. Data on vital status was obtained for patients with mild cognitive impairment who were treated with galantamine or placebo in previous 3 clinical studies.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Janssen R&D US
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Johnson & Johnson Pharmaceutical Research & Development, LLC C. Clinical Trial
Role: STUDY_DIRECTOR
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tucson, Arizona, United States
Laguna Woods, California, United States
Northridge, California, United States
Oceanside, California, United States
Paramount, California, United States
San Diego, California, United States
San Francisco, California, United States
Hamden, Connecticut, United States
Hartford, Connecticut, United States
New Haven, Connecticut, United States
Fort Lauderdale, Florida, United States
Miami, Florida, United States
North Miami, Florida, United States
Oscala F, Florida, United States
St. Petersburg, Florida, United States
West Palm Beach, Florida, United States
Atlanta, Georgia, United States
Chicago, Illinois, United States
Paducah, Kentucky, United States
Glen Burnie, Maryland, United States
Rockville, Maryland, United States
Boston, Massachusetts, United States
Pittsfield, Massachusetts, United States
Farmington Hills, Michigan, United States
Kalamazoo, Michigan, United States
Clementon, New Jersey, United States
Ridgewood, New Jersey, United States
Summit, New Jersey, United States
Albany, New York, United States
New Hyde Park, New York, United States
New York, New York, United States
Rochester, New York, United States
Staten Island, New York, United States
The Bronx, New York, United States
Durham, North Carolina, United States
Columbus, Ohio, United States
Toledo, Ohio, United States
Tulsa, Oklahoma, United States
Portland, Oregon, United States
Pittsburgh, Pennsylvania, United States
East Providence, Rhode Island, United States
Providence, Rhode Island, United States
Austin, Texas, United States
Dallas, Texas, United States
Houston, Texas, United States
Wichita Falls, Texas, United States
Bennington, Vermont, United States
Richmond, Virginia, United States
Tacoma, Washington, United States
Middleton, Wisconsin, United States
Buenos Aires, , Argentina
Córdoba, , Argentina
Adelaide, , Australia
Christchurch Nz, , Australia
Hornsby Streets, , Australia
Kew, , Australia
Parkville, , Australia
Perth, , Australia
Randwick, , Australia
Woodville, , Australia
Graz, , Austria
Innsbruck, , Austria
Vienna, , Austria
Aalst, , Belgium
Antwerp, , Belgium
Hasselt, , Belgium
Jumet, , Belgium
Leuven, , Belgium
Liège, , Belgium
Merksem, , Belgium
Reet, , Belgium
Roeselare, , Belgium
Wilrijk, , Belgium
Edmonton, Alberta, Canada
Vancouver, British Columbia, Canada
Moncton, New Brunswick, Canada
Saint John, New Brunswick, Canada
Halifax, Nova Scotia, Canada
Barrie, Ontario, Canada
Hamilton, Ontario, Canada
Kingston, Ontario, Canada
London, Ontario, Canada
North York, Ontario, Canada
Ottawa, Ontario, Canada
Toronto, Ontario, Canada
Greenfield Park, Quebec, Canada
Pointe-Claire, Quebec, Canada
Québec, Quebec, Canada
Verdun, Quebec, Canada
Saskatoon, Saskatchewan, Canada
London, , Canada
Montreal, , Canada
North York, , Canada
T2n, , Canada
Chomutov, , Czechia
Dobřany, , Czechia
Hluboká nad Vltavou, , Czechia
Kolín, , Czechia
Opava, , Czechia
Praha 8 N/A, , Czechia
Rennes Cedex, , Czechia
Ústí nad Labem, , Czechia
Helsinki, , Finland
Kuopio, , Finland
Toulouse, , France
Berlin, , Germany
Frankfurt am Main, , Germany
Mannheim, , Germany
München, , Germany
Nuremberg, , Germany
Ulm, , Germany
Haifa, , Israel
Petach Tikya, , Israel
Ramat Gan, , Israel
Tel Aviv, , Israel
's-Hertogenbosch, , Netherlands
Alkmaar, , Netherlands
Amsterdam, , Netherlands
Breda, , Netherlands
Maastricht, , Netherlands
Gdansk, , Poland
Katowice Poland, , Poland
Lodz, , Poland
Mosina Poland, , Poland
Poznan, , Poland
Poznan Poland, , Poland
Warsaw, , Poland
Barakaldo Vizcaya S/N, , Spain
Barcelona, , Spain
Madrid, , Spain
Terrasa Barcelona N/A, , Spain
Linköping, , Sweden
Lund, , Sweden
Malmo, , Sweden
Mölndal, , Sweden
Piteå, , Sweden
Stockholm, , Sweden
Umeå, , Sweden
Bradford, , United Kingdom
Bristol, , United Kingdom
Clydebank, , United Kingdom
New Milton, , United Kingdom
Southampton, , United Kingdom
Swindon, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Survey of the vital status of patients who participated in three studies of galantamine in treatment of mild cognitive impairment.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GAL-COG-3002
Identifier Type: OTHER
Identifier Source: secondary_id
CR004240
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.